Female Reproductive & Breast

Sexual dysfunction in women: evaluation and management

Clinical Overview and When to Suspect Female Sexual Dysfunction

— Female Sexual Interest/Arousal Disorder (FSIAD): merged low desire + arousal problems

— Female Orgasmic Disorder: delay, absence, or reduced intensity of orgasm

— Genito-Pelvic Pain/Penetration Disorder (GPPPD): subsumes prior dyspareunia + vaginismus

— Routine visits where the patient mentions decreased libido, vaginal dryness, painful intercourse, anorgasmia, or relationship strain

— After major life transitions: childbirth, breastfeeding, menopause, cancer treatment, new SSRI, divorce/bereavement

— Chronic disease visits (diabetes, MS, depression, CKD) where dysfunction is often unscreened

— Use a normalizing open-ended question: "Many women have changes in sexual function — are you having any concerns?"

— Validated tools: Female Sexual Function Index (FSFI) and Brief Sexual Symptom Checklist for documentation and tracking

— Always ask about distress — drives whether to treat

— Biologic: hormones, vascular, neurologic, medications

— Psychologic: depression, anxiety, prior trauma, body image

— Interpersonal: partner health, relationship quality, intimate partner violence

— Sociocultural: religion, cultural norms, sexual orientation

Board pearl: Distress is the gatekeeper diagnostic criterion — a woman with low desire who is not bothered by it does not have FSIAD and does not need pharmacotherapy. Document distress explicitly before initiating treatment.

Definition: Female sexual dysfunction (FSD) encompasses persistent or recurrent problems in desire, arousal, orgasm, or sexual pain that cause personal distress for ≥6 months (DSM-5 threshold). Distress is required — absence of sexual activity without distress is not a disorder.

DSM-5 categories (simplified):

Epidemiology: ~40% of US women report a sexual concern; ~12% meet distress criteria. Peaks in perimenopause/menopause and postpartum.

When to suspect on Step 3:

Screening approach (ambulatory/Step 3 voice):

Biopsychosocial framing is mandatory:

Presentation Patterns and Key History

— Desire: frequency of sexual thoughts/fantasy, initiation, responsive vs spontaneous desire (responsive desire — arousal precedes desire — is normal in long-term partnerships)

— Arousal: subjective excitement, lubrication, genital sensation

— Orgasm: ability, latency, intensity, change from baseline

— Pain: location (entry vs deep), timing (with penetration, mid-coitus, post-coital), quality

— Lifelong vs acquired: lifelong anorgasmia suggests psychogenic or never-learned; acquired suggests medication, hormonal, or relational cause

— Generalized vs situational: situational (with one partner only, or not with masturbation) points to interpersonal or psychogenic, not biologic

— Menopausal status, LMP, vasomotor symptoms, vaginal dryness → genitourinary syndrome of menopause (GSM)

— Obstetric: parity, mode of delivery, perineal trauma, breastfeeding (hypoestrogenic state)

— Endocrine: thyroid, diabetes, hyperprolactinemia, adrenal insufficiency

— Neurologic: MS, spinal cord injury, neuropathy

— Oncologic: breast/pelvic cancer, chemo, pelvic radiation, aromatase inhibitors

— Psychiatric: depression, anxiety, PTSD, eating disorders

— SSRIs/SNRIs (decreased desire, anorgasmia — up to 70%)

— OCPs (↑SHBG, ↓free testosterone)

— Beta-blockers, spironolactone, opioids, antipsychotics

— Tamoxifen, aromatase inhibitors, GnRH agonists

— Partner sexual function (erectile dysfunction in partner is a common driver)

— Always screen for intimate partner violence and sexual trauma privately

— Relationship satisfaction, communication, infidelity

Step 3 management: When SSRI-induced dysfunction is identified, options include dose reduction, switching to bupropion or mirtazapine, adding bupropion, or a drug holiday — but only after confirming psychiatric stability.

Core history domains — ask in this order to mirror the sexual response cycle:

Onset and context clarify etiology:

Targeted medical history:

Medication review — high-yield culprits:

Relational and trauma history:

Physical Exam Findings (and Pelvic Assessment)

— Vulvar skin: lichen sclerosus (white, atrophic, "cigarette paper"), lichen planus (erosive, Wickham striae), vulvar dermatitis, vitiligo

— Atrophic changes (GSM): pale, thin, dry mucosa; loss of rugae; narrowed introitus; petechiae; urethral caruncle

— Vestibule: Q-tip test — light touch at 5 and 7 o'clock positions reproduces pain in provoked vestibulodynia

— Episiotomy scars, fissures, condylomata

— Use smallest comfortable speculum, warm, well-lubricated

— Vaginal pH >5 supports atrophy/GSM

— Cervical findings, discharge, lesions

— Pelvic floor muscle tone: hypertonic levator ani → reproduces dyspareunia and suggests pelvic floor dysfunction/vaginismus spectrum

— Cervical motion tenderness, adnexal masses, uterine tenderness → consider endometriosis, PID, fibroids

— Deep dyspareunia on uterosacral palpation → endometriosis

— Perineal sensation (S2–S4), anal tone, bulbocavernosus reflex if neurogenic etiology suspected (MS, cauda equina, diabetic neuropathy)

Key distinction: Superficial/entry dyspareunia localizes to vulvovestibular, atrophic, or pelvic floor causes; deep dyspareunia points to endometriosis, adenomyosis, fibroids, PID, or pelvic adhesions. Differentiating these on exam directs imaging and referral choices.

Board pearl: A positive Q-tip test with otherwise normal exam is essentially diagnostic of provoked vestibulodynia — no further imaging needed before initiating topical lidocaine and pelvic floor PT.

General exam: Body habitus, thyroid, hair distribution (hirsutism → PCOS/hyperandrogenism), galactorrhea (hyperprolactinemia), signs of systemic illness or depression.

External genital inspection (with chaperone, patient consent, trauma-informed approach):

Speculum exam:

Bimanual exam:

Neurologic check when indicated:

Defer or modify exam if trauma history: offer self-insertion of speculum, allow patient to stop at any time, schedule a return visit if needed.

Diagnostic Workup — Initial Labs and Targeted Studies

— TSH if fatigue, weight changes, menstrual irregularity, or low libido without obvious cause

— Prolactin if galactorrhea, amenorrhea, or new-onset low desire (rule out prolactinoma, especially with antipsychotics)

— FSH/estradiol only if menopausal status is unclear (e.g., post-hysterectomy with ovaries, irregular cycles <45) — otherwise diagnose menopause clinically

— Total + free testosterone, SHBG, DHEAS: routine testosterone screening is not recommended in healthy women with low desire (poor correlation with symptoms); obtain only if considering off-label androgen therapy or hyperandrogenism is suspected

— PHQ-9 and GAD-7 in every FSD workup — psychiatric comorbidity is bidirectional and treatable

— Screen for trauma (PCL-5) and substance use (AUDIT-C)

— Transvaginal ultrasound for deep dyspareunia, pelvic mass, abnormal bleeding, or suspected fibroids/adenomyosis

— Pelvic MRI if deep infiltrating endometriosis suspected and surgery contemplated

Step 3 management: In the ambulatory setting, the highest-yield "labs" are PHQ-9, GAD-7, TSH, prolactin, and a complete medication review — these identify reversible contributors in the majority of cases without expensive imaging.

FSD is primarily a clinical diagnosis — labs are selective, driven by history and exam. Do not order a "sexual dysfunction panel" reflexively.

When to obtain hormonal labs:

Glucose/A1c, lipid panel: Diabetes and metabolic syndrome contribute to arousal/lubrication problems via microvascular and neuropathic mechanisms.

Depression and anxiety screening:

STI testing when indicated by pain, discharge, new partners, or risk factors.

Pregnancy test when relevant before any pharmacotherapy.

Imaging — only with directed findings:

Vulvar biopsy: any persistent, atypical, white/hyperkeratotic, or ulcerated lesion — required to diagnose lichen sclerosus definitively and exclude vulvar intraepithelial neoplasia or SCC.

Diagnostic Workup — Advanced or Confirmatory Studies

— Gold-standard functional assessment for hypertonic pelvic floor, vaginismus, dyspareunia, levator myalgia

— Internal muscle palpation grades tone, trigger points, and coordination

— Often diagnostic and therapeutic in the same visit pathway

— When dyspareunia coexists with urinary urgency, dysuria, or post-coital UTI symptoms → consider interstitial cystitis/bladder pain syndrome

— Potassium sensitivity test is largely historical; cystoscopy with hydrodistension may show Hunner lesions

— Persistent vulvar pain with visible changes; acetic acid application can highlight neoplasia

— Biopsy mandatory for suspected lichen sclerosus (lymphocytic band on histology) — also screens for SCC risk (~4–5%)

— Pudendal nerve block (diagnostic + therapeutic) for pudendal neuralgia (Nantes criteria: pain in pudendal territory, worsened by sitting, no nocturnal pain, no sensory deficit)

— EMG/MRI for suspected sacral radiculopathy or MS

— Repeat morning prolactin and pituitary MRI if persistently elevated

— 17-OH progesterone, free testosterone, DHEAS for hyperandrogenism

— Referral to a certified sex therapist (AASECT) when relational, trauma, or identity factors dominate

— Especially important for lifelong anorgasmia, vaginismus, sexual aversion disorder

— MRI pelvis for deep endometriosis, adenomyosis, pelvic floor anatomic defects

— Defecography if obstructed defecation or rectocele contributes to dyspareunia

CCS pearl: Order pelvic floor PT consultation early in any case of dyspareunia with normal pelvic imaging — it both confirms hypertonic pelvic floor dysfunction and initiates first-line therapy, advancing the case clock efficiently.

Referral-driven advanced workup — most patients do not need it, but recognize the indications.

Pelvic floor physical therapist evaluation:

Urodynamics / cystoscopy:

Vulvoscopy and biopsy:

Neurologic studies:

Endocrine confirmation:

Psychosexual evaluation:

Imaging adjuncts:

First-Line Management Logic and Risk Stratification

— Step 1: Treat reversible causes (medications, depression, hypothyroidism, GSM, relationship stressors)

— Step 2: Behavioral/psychological interventions (education, CBT, sex therapy, mindfulness)

— Step 3: Targeted pharmacotherapy or devices

— Step 4: Specialist referral

— Normalize responsive desire in long-term relationships

— Explain the dual control model (excitation vs inhibition) and the role of context, fatigue, stress

— Address myths (e.g., women must orgasm via penetration alone — only ~25% do)

— Sensate focus exercises (graded non-demand touching)

— Communication training

— Treat partner's dysfunction (e.g., partner's ED) — often unlocks the patient's response

— Exercise, sleep, stress reduction, alcohol moderation

— Smoking cessation (vascular effects on arousal)

— GSM-predominant: start with vaginal moisturizers + lubricants, escalate to low-dose vaginal estrogen or DHEA (prasterone) or ospemifene

— HSDD/FSIAD in premenopausal women: consider flibanserin or bremelanotide after non-pharmacologic measures

— HSDD in postmenopausal women: off-label transdermal testosterone (low dose) is the only androgen with reasonable evidence

— GPPPD/dyspareunia: pelvic floor PT + topical lidocaine ± vaginal dilators ± CBT

— Orgasmic disorder: directed masturbation training, vibrator use, CBT; switch SSRI if drug-induced

— Discuss modest effect sizes of pharmacotherapy (e.g., flibanserin adds ~0.5–1 satisfying sexual event/month)

— Cost, insurance coverage, side effects

Board pearl: Always discontinue or substitute the offending medication before adding a new drug — switching from an SSRI to bupropion often resolves FSD without further intervention.

Frame management around the dominant problem (desire vs arousal vs orgasm vs pain) and reversible contributors, in this order:

Patient education is foundational:

Couples-based approach when partnered:

Lifestyle modifications:

Risk stratification by subtype:

Shared decision-making:

Pharmacotherapy — First-Line Drug Regimens

— Vaginal moisturizers (hyaluronic acid, polycarbophil) 2–3×/week + lubricants with intercourse (water- or silicone-based)

— Low-dose vaginal estrogen (cream, tablet, ring) — first-line for moderate-severe GSM; minimal systemic absorption; no progestin required with low-dose vaginal regimens

— Vaginal DHEA (prasterone) 6.5 mg insert daily — alternative; locally converted to estrogen + androgen

— Ospemifene 60 mg PO daily — oral SERM, FDA-approved for moderate-severe dyspareunia; risk of hot flashes, VTE

— Flibanserin 100 mg PO at bedtime — 5-HT1A agonist/5-HT2A antagonist

— Black box: hypotension/syncope with alcohol (avoid alcohol within 2 hr) and CYP3A4 inhibitors; modest efficacy

— Bremelanotide 1.75 mg SC PRN ≥45 min before sexual activity — melanocortin agonist; side effects: nausea (40%), transient BP rise, hyperpigmentation

— Transdermal testosterone targeting premenopausal physiologic range (~300 µg/day); monitor total testosterone q3–6 months; avoid in breast/uterine cancer history

— No oral testosterone (hepatotoxicity, lipid effects)

— Switch to bupropion or mirtazapine, or augment with bupropion 150–300 mg/day

— Vilazodone, vortioxetine have lower rates than other SSRIs

— Sildenafil has modest evidence for SSRI-induced anorgasmia in women

— Topical lidocaine 5% ointment nightly or pre-coitus

— Adjuncts: TCAs (amitriptyline, nortriptyline), gabapentin/pregabalin for neuropathic component

— Topical compounded gabapentin or amitriptyline

Step 3 management: Before prescribing flibanserin, document HSDD diagnosis, premenopausal status, absence of hepatic impairment, no concurrent CYP3A4 inhibitors, and counseling on alcohol avoidance — REMS-style documentation is high-yield.

Genitourinary syndrome of menopause (GSM) / postmenopausal dyspareunia:

Hypoactive sexual desire disorder (HSDD) — premenopausal:

HSDD — postmenopausal (off-label in US):

SSRI-induced sexual dysfunction:

Vulvodynia/provoked vestibulodynia:

Devices, Procedures, and Expanded Non-Pharmacologic Therapy

— Biofeedback, manual trigger point release, stretching, relaxation training

— Course typically 8–12 sessions; evidence-based and first-line

— Graded sizes used progressively under PT guidance

— Indicated for vaginismus, post-radiation vaginal stenosis, post-surgical scarring

— Combine with topical lidocaine and relaxation techniques

— CBT for anxiety, catastrophizing, body image

— Sensate focus (Masters and Johnson) for couples

— Mindfulness-based therapy has growing evidence in HSDD and arousal disorders

— Clitoral vacuum device (Eros) — FDA-cleared for arousal disorder; increases blood flow

— Vibrators — first-line for primary anorgasmia and directed masturbation training

— Vaginal weights/cones for pelvic floor strengthening when hypotonic floor contributes (less common than hypertonic)

— Trigger point injections (lidocaine ± steroid) into pelvic floor muscles for refractory myofascial pain

— Pudendal nerve block for pudendal neuralgia

— Botulinum toxin injection into levator ani — emerging evidence for refractory vaginismus and high-tone pelvic floor dysfunction

— Vestibulectomy — surgical excision of vestibular mucosa; reserved for refractory provoked vestibulodynia after failed conservative therapy (high success but irreversible)

— Marketed for GSM/vaginal rejuvenation

— FDA safety communication (2018) warned against marketing for these indications; evidence remains insufficient

— Not recommended outside clinical trials

Key distinction: Vaginismus responds primarily to pelvic floor PT + dilators + CBT, not to estrogen — distinguishing it from GSM is essential before prescribing.

Pelvic floor physical therapy — cornerstone for dyspareunia, vaginismus, vulvodynia, levator myalgia:

Vaginal dilator therapy:

Cognitive behavioral therapy and sex therapy:

Devices and adjuncts:

Procedural interventions for specific conditions:

Energy-based devices (CO2 laser, radiofrequency):

Special Populations — Elderly and Renal/Hepatic Impairment

— GSM (nearly universal untreated postmenopausal women)

— Comorbid chronic disease (diabetes, CVD, arthritis affecting positioning)

— Polypharmacy

— Partner availability and partner health (widowhood, partner ED, partner cognitive decline)

— Low-dose vaginal estrogen is safe long-term, including in many breast cancer survivors after oncology discussion (data reassuring; not contraindicated in most)

— Vaginal DHEA and ospemifene are alternatives

— Avoid systemic hormone therapy initiation in women >60 or >10 years from menopause (cardiovascular risk per WHI reanalysis)

— Flibanserin contraindicated — increases drug exposure substantially

— Ospemifene: use caution; limited data in severe hepatic impairment

— Oral estrogens increase hepatic protein synthesis (avoid; prefer transdermal/vaginal)

— No major dose adjustments needed for vaginal estrogen, DHEA, or ospemifene

— Bremelanotide: avoid in severe renal impairment (limited data, transient BP elevation)

— Gabapentin/pregabalin (for vulvodynia) — renally dosed

— Bremelanotide causes transient ~6 mmHg rise in BP — avoid in uncontrolled hypertension or known CVD

— Flibanserin → orthostatic hypotension, especially with alcohol or CYP3A4 inhibitors common in elderly polypharmacy

— Arthritis: positioning advice, lubricants, scheduling around pain medication

— Vision/dexterity: applicator choice for vaginal therapies

Board pearl: In a breast cancer survivor on aromatase inhibitor with severe GSM unresponsive to nonhormonal therapy, low-dose vaginal estrogen or DHEA may be considered after shared decision-making with oncology — it is no longer an absolute contraindication.

Older women remain sexually active — ~40% of women 65–80 report sexual activity; do not assume otherwise. Ask explicitly.

Predominant issues in older women:

GSM management in elderly:

Hepatic impairment:

Renal impairment:

Cardiovascular caution:

Functional considerations:

Special Populations — Pregnancy, Postpartum, Cancer Survivors, LGBTQ+

— Sexual activity is safe in uncomplicated pregnancy; avoid in placenta previa, preterm labor risk, PPROM, cervical insufficiency

— Desire and frequency often decrease in 1st and 3rd trimesters

— Counsel on positional changes; reassure about fetal safety

— Dyspareunia affects ~40–60% at 3 months postpartum; ~20% at 12 months

— Contributors: perineal trauma, breastfeeding-induced hypoestrogenism (vaginal atrophy), fatigue, body image, mood

— Management: water-based lubricants, vaginal moisturizers, topical estrogen if severe atrophy (safe with breastfeeding), pelvic floor PT for levator dysfunction

— Screen for postpartum depression (PHQ-9, EPDS) — strongly correlated with FSD

— Breast, gynecologic, colorectal cancers all impact sexual function via surgery, chemo, radiation, antiestrogens

— Vaginal stenosis after pelvic radiation — prevent with early dilator use

— Aromatase inhibitors → severe GSM; ospemifene, DHEA, vaginal estrogen (with oncology input) options

— Body image after mastectomy/colostomy — refer to oncology rehab and counseling

— Use inclusive, gender-affirming language; ask about anatomy, partners, practices separately from identity

— Lesbian and bisexual women have similar prevalence of FSD; do not assume penetrative concerns

— Transgender men on testosterone may develop vaginal atrophy — vaginal estrogen is safe and does not affect masculinization

— Trauma-informed care: explicit consent, control over exam pacing, option to defer

— Refer to trauma-focused CBT, EMDR; coordinate with mental health

Step 3 management: For postpartum dyspareunia at the 6-week visit, first-line is reassurance, lubrication, pelvic floor exercises, and screening for PPD — pharmacotherapy is rarely needed before 3–6 months postpartum.

Pregnancy:

Postpartum:

Cancer survivors:

LGBTQ+ women:

Survivors of sexual trauma:

Complications and Adverse Outcomes

— Persistent personal distress, depression, anxiety

— Relationship deterioration, decreased intimacy, separation/divorce

— Avoidance of routine pelvic care (Pap, mammography, STI screening) due to shame

— Decreased quality of life metrics comparable to chronic medical illness

— Lichen sclerosus: untreated → progressive scarring, labial resorption, clitoral phimosis, introital stenosis, vulvar SCC (~4–5% lifetime risk) — mandates long-term topical clobetasol and annual exams

— Vulvodynia: chronic pain syndrome with central sensitization, often comorbid fibromyalgia, IBS, interstitial cystitis

— Vaginismus: unconsummated marriage, infertility from inability to have intercourse

— GSM: recurrent UTIs, urinary urgency/incontinence, vaginal infections, fissuring

— Flibanserin: syncope, hypotension (especially with alcohol)

— Bremelanotide: focal hyperpigmentation (face, breasts, gums) in ~1%, often persistent; nausea, transient hypertension

— Ospemifene: hot flashes, leg cramps, VTE (low absolute risk)

— Systemic estrogen (if used): VTE, stroke, breast cancer risk in long-term use >60 yr

— Vaginal estrogen: very low risk of endometrial hyperplasia at low doses; spotting warrants evaluation

— Testosterone: acne, hirsutism, voice deepening (irreversible) if supraphysiologic, virilization, lipid changes

— Vestibulectomy: scarring, worsening pain in subset, irreversibility

— Inappropriate prescribing of testosterone without baseline labs

— Energy-based devices outside clinical trials

— Compounded "bioidentical hormones" without standardized dosing or oversight

Board pearl: Any postmenopausal bleeding in a woman using vaginal estrogen requires endometrial evaluation (TVUS ± biopsy) — do not attribute to local therapy.

Untreated FSD consequences:

Complications of specific conditions:

Treatment-related complications:

Iatrogenic harm to avoid:

When to Escalate Care — Referral and Multidisciplinary Triage

— Refractory dyspareunia despite 3 months of first-line therapy

— Suspected deep infiltrating endometriosis, adenomyosis, fibroids requiring surgical evaluation

— Vulvar dermatosis requiring biopsy or refractory to topical steroids

— Pelvic organ prolapse contributing to sexual dysfunction

— Consideration of testosterone therapy (specialist comfort)

— Any dyspareunia, vaginismus, vulvodynia, or post-surgical/post-radiation sexual dysfunction

— Early referral is high-yield and underutilized

— Trauma history, sexual aversion, relational conflict, lifelong anorgasmia

— Comorbid major depression, anxiety, PTSD

— AASECT-certified sex therapists for couples and individual sex therapy

— Persistent hyperprolactinemia, suspected pituitary adenoma

— Adrenal androgen disorders

— Interstitial cystitis/bladder pain syndrome

— Recurrent UTIs with sexual activity

— Stress urinary incontinence affecting intimacy

— Suspected MS, neuropathy, pudendal neuralgia, sacral radiculopathy

— Suicidal ideation related to sexual or relationship distress → emergency psychiatric evaluation

— Acute presentation of intimate partner violence → social work, safety planning, mandatory reporting per jurisdiction

— Severe vulvar cellulitis, abscess, or suspected SCC → urgent surgical consultation

— Primary care typically quarterbacks — initiate evaluation, treat reversible causes, refer in parallel rather than serially

CCS pearl: For dyspareunia in the ambulatory CCS case, simultaneously order pelvic exam, PHQ-9, TSH, and pelvic floor PT referral — parallel ordering advances the case efficiently and reflects real-world practice.

Refer to gynecology or specialist in sexual medicine when:

Refer to pelvic floor physical therapy:

Refer to mental health/sex therapy:

Refer to endocrinology:

Refer to urology/urogynecology:

Refer to neurology:

Inpatient escalation is rare in FSD but consider:

Care coordination:

Key Differentials — Within the Sexual Dysfunction Category

— Persistent ↓ desire and/or ↓ subjective/genital arousal × ≥6 months with distress

— Treat: address reversible causes, sex therapy, ± flibanserin/bremelanotide (premenopausal), ± testosterone (postmenopausal, off-label)

— Delayed, absent, or markedly reduced orgasm despite adequate arousal

— Lifelong → directed masturbation, CBT, vibrators

— Acquired → identify trigger (SSRI, relational, medical); switch antidepressant

— Pain with penetration, fear/anxiety, pelvic floor tightening

— Encompasses prior dyspareunia + vaginismus

— Treat: pelvic floor PT, dilators, CBT, topical lidocaine, treat underlying pathology

— SSRIs/SNRIs, antipsychotics, opioids, beta-blockers, OCPs, alcohol

— Diagnosis requires temporal relationship and resolution with discontinuation

— Diabetes, MS, CKD, depression, hypothyroidism, hyperprolactinemia

— Distinct DSM-5 category when condition is the clear cause

— Unwanted, intrusive genital arousal without subjective desire

— Distinct from HSDD; associated with sacral nerve pathology, SSRI discontinuation, pelvic varices

— Refer to specialist

Key distinction: A woman reporting "no interest in sex" needs careful parsing — lack of spontaneous desire with intact responsive desire and no distress is NORMAL and not FSIAD. A woman with distressing absence of both spontaneous and responsive desire meets criteria. Step 3 questions test this nuance frequently.

Board pearl: Vaginismus and provoked vestibulodynia are often mislabeled; the differentiator is the Q-tip test — positive at vestibule → vestibulodynia; negative with reflexive pelvic floor spasm on attempted penetration → vaginismus (now both under GPPPD).

Distinguishing FSD subtypes is essential because treatments differ.

Female Sexual Interest/Arousal Disorder (FSIAD):

Female Orgasmic Disorder:

Genito-Pelvic Pain/Penetration Disorder (GPPPD):

Substance/medication-induced sexual dysfunction:

Sexual dysfunction due to another medical condition:

Persistent Genital Arousal Disorder (PGAD/GPLA):

Key Differentials — Other-Category Causes Masquerading as FSD

— Deep dyspareunia, dysmenorrhea, infertility, cyclic pelvic pain

— Exam: tender uterosacral nodularity, fixed retroverted uterus

— Workup: TVUS, MRI; definitive diagnosis by laparoscopy

— Treat: NSAIDs, combined OCPs, progestins, GnRH analogs, surgery

— Cervical motion tenderness, adnexal tenderness, STI history

— Treat per CDC: ceftriaxone + doxycycline ± metronidazole

— Bulk symptoms, heavy menstrual bleeding, deep dyspareunia

— Imaging: TVUS, MRI; treat per symptoms (medical or surgical)

— Urinary urgency, frequency, suprapubic pain worsened by bladder filling, dyspareunia

— Diagnosis clinical ± cystoscopy; multimodal therapy

— Bulge symptoms, splinting, sensation of "something falling out"

— Pessary, pelvic floor PT, surgery

— Lichen sclerosus, lichen planus, lichen simplex chronicus, contact dermatitis

— Biopsy if uncertain; clobetasol for lichen sclerosus/planus

— Recurrent candidiasis, bacterial vaginosis, trichomoniasis, HSV

— Treat empirically with culture/NAAT confirmation

— Major depression, generalized anxiety, PTSD, eating disorders — all suppress desire and arousal

— Treat primary disorder; choose antidepressants with lower sexual side effects when possible

— Hypothyroidism, hyperprolactinemia, diabetes, adrenal insufficiency, premature ovarian insufficiency

— MS, spinal cord injury, diabetic autonomic neuropathy, pudendal neuralgia

Step 3 management: A 32-year-old with deep dyspareunia, dysmenorrhea, and infertility — work up for endometriosis (TVUS, refer GYN, consider empirical OCPs) rather than labeling as primary FSD.

Endometriosis:

Pelvic inflammatory disease / chronic PID:

Fibroids / adenomyosis:

Interstitial cystitis/bladder pain syndrome:

Pelvic organ prolapse:

Vulvar dermatoses:

Infectious causes:

Psychiatric:

Endocrine:

Neurologic:

Intimate partner violence and sexual trauma — must be actively screened; can present as any FSD subtype.

Secondary Prevention, Maintenance, and Long-Term Plan

— GSM: continue vaginal estrogen/DHEA/ospemifene indefinitely — symptoms recur within weeks of discontinuation; consider lowest effective frequency (e.g., 1–2×/week vaginal estrogen)

— Lichen sclerosus: taper to maintenance topical clobetasol 1–2×/week lifelong; annual surveillance for SCC

— Vulvodynia/GPPPD: taper neuromodulators (TCAs, gabapentinoids) after sustained remission ≥6 months; continue pelvic floor home program

— Vaginismus: continue dilator maintenance until consistent comfort with intercourse; periodic refresher PT

— HSDD on flibanserin/bremelanotide: reassess at 8 weeks; discontinue flibanserin if no benefit by 8 weeks

— Reassess SSRIs, OCPs, antihypertensives that contribute to dysfunction

— Consider dose reductions or alternatives during psychiatric remission

— Exercise, sleep, stress management, alcohol moderation, smoking cessation

— Address partner health (e.g., partner ED treatment improves the patient's function)

— Cervical cancer screening per USPSTF (Pap/HPV)

— Mammography per guidelines

— STI screening based on risk

— Bone density in women on aromatase inhibitors or hypoestrogenic states

— HPV vaccination through age 45 (shared decision 27–45)

— HSV counseling; consider suppressive therapy if recurrent and contributing to dyspareunia

— Encourage ongoing couples communication

— Refresher sex therapy at major transitions (perimenopause, retirement, illness)

Board pearl: GSM symptoms recur quickly after stopping vaginal estrogen — counsel patients that this is chronic maintenance therapy, analogous to treating any chronic condition.

Long-term goals: sustain treatment response, prevent recurrence, monitor adverse effects, address evolving life-stage needs.

Maintenance regimens by condition:

Medication review at every visit:

Lifestyle reinforcement:

Preventive care integration:

Vaccinations:

Relationship maintenance:

Follow-Up, Monitoring Parameters, and Counseling

— 4–8 weeks after starting any new therapy (GSM regimen, flibanserin, ospemifene, topical lidocaine, pelvic floor PT initiation)

— Reassess symptoms (FSFI score change), distress, adherence, side effects

— Flibanserin: discontinue at 8 weeks if no meaningful improvement; screen for syncope, hypotension, alcohol use, somnolence

— Bremelanotide: monitor BP at baseline and follow-up; counsel on nausea, focal hyperpigmentation

— Ospemifene: assess hot flashes, leg cramps; counsel on VTE symptoms

— Vaginal estrogen: annual evaluation; investigate any bleeding

— Testosterone (off-label): total testosterone q3–6 months, lipids, LFTs, screen for virilization

— Reassess at 6–8 sessions; home exercise adherence is key

— Continue maintenance program after discharge

— Track PHQ-9/GAD-7; coordinate with mental health provider

— Reassess relationship stress, IPV screening at intervals

— Set realistic expectations: pharmacotherapy effect sizes are modest

— Frame therapy as multimodal — drugs alone rarely sufficient

— Address partner involvement when appropriate

— Use validated tools (FSFI) to track objective change

— ISSWSH, NAMS (menopause), AASECT patient resources

— Reputable books and apps (e.g., mindfulness-based programs)

— Reassess goals, life-stage changes, medication updates

— Re-screen for IPV, trauma, depression

— Update sexual history (new partners, identity, practices)

Step 3 management: Document a shared decision-making conversation including alternatives, expected benefit magnitude, and side effects before initiating flibanserin or bremelanotide — this is both REMS-aligned and exam-favored.

Initial follow-up cadence:

Pharmacotherapy-specific monitoring:

Pelvic floor PT:

Mental health follow-up:

Counseling pearls (high-yield communication):

Patient education resources:

Long-term annual review:

Ethical, Legal, and Patient Safety Considerations

— Quantify the modest effect size of FDA-approved HSDD drugs (flibanserin adds ~0.5–1 satisfying sexual event/month vs placebo) — exam often tests realistic counseling

— For off-label testosterone, document baseline labs, discussion of unknown long-term risks, and absence of safer alternatives

— For surgical interventions (vestibulectomy), discuss irreversibility and alternative conservative therapy completion

— Sexual dysfunction may be the presenting symptom of IPV; screen privately, without partner in room

— USPSTF recommends screening women of reproductive age

— If IPV identified: safety assessment, resources (national hotline 1-800-799-7233), documentation, safety planning

— Mandatory reporting varies by state — most US states do not mandate IPV reporting in competent adults (unlike child/elder abuse); know your jurisdiction

— Suspected child sexual abuse disclosed during evaluation → mandatory report to CPS in all 50 states

— Elder/vulnerable adult abuse — mandatory report per state law

— Sexual assault: offer evidence collection, prophylaxis, support — reporting to law enforcement is patient's choice in most jurisdictions for adult competent victims

— Confidential sexual history; state minor consent laws vary

— Document confidential portions appropriately

— Avoid heteronormative assumptions; ask about partners and practices

— Religious/cultural values may affect treatment choices; respect autonomy

— Always offer a chaperone for pelvic exams; document offer and acceptance/decline

— Trauma-informed consent for each step of the exam

— When initiating flibanserin, ensure communication with all prescribers about CYP3A4 interactions and alcohol counseling

— Pharmacy reconciliation on every visit

— Counsel against unregulated "vaginal rejuvenation" energy devices and compounded bioidentical hormones lacking evidence

Board pearl: A patient discloses historical childhood sexual abuse during FSD evaluation — this is not a mandatory current report unless the perpetrator has ongoing access to children; document, validate, and refer for trauma-focused therapy.

Informed consent and shared decision-making:

Intimate partner violence (IPV):

Mandatory reporting:

Confidentiality and adolescents:

Cultural humility:

Boundary safety:

Transition-of-care safety:

Avoid pseudoscience:

High-Yield Associations and Rapid-Fire Clinical Facts

Key distinction: Spontaneous desire ≠ responsive desire; only distressing absence of both with intact context constitutes FSIAD. Pattern-matching this single concept answers many Step 3 vignettes.

Distress is mandatory for any FSD diagnosis — no distress, no disorder.

Responsive desire is normal in long-term relationships — does not require treatment.

SSRIs cause sexual dysfunction in up to 70% — bupropion and mirtazapine are lowest risk.

Bupropion is the go-to switch/augment for SSRI-induced FSD.

Flibanserin = premenopausal HSDD; daily dosing; avoid alcohol; CYP3A4 caution.

Bremelanotide = premenopausal HSDD; PRN SC injection; nausea, transient HTN, focal hyperpigmentation.

Ospemifene = postmenopausal dyspareunia (GSM); oral SERM.

Vaginal DHEA (prasterone) = postmenopausal GSM/dyspareunia.

Low-dose vaginal estrogen = first-line GSM pharmacotherapy; no progestin needed.

Lichen sclerosus = "cigarette paper" atrophic plaques; clobetasol is first-line; lifelong follow-up; 4–5% SCC risk.

Provoked vestibulodynia → positive Q-tip test; treat with topical lidocaine + pelvic floor PT.

Vaginismus (under GPPPD) → pelvic floor PT + graded dilators + CBT.

Endometriosis → deep dyspareunia + dysmenorrhea + infertility; uterosacral nodularity.

Postpartum dyspareunia → breastfeeding atrophy + perineal healing + PPD; lubrication + reassurance first.

Aromatase inhibitor users with severe GSM may use vaginal DHEA, ospemifene, or low-dose vaginal estrogen after oncology discussion.

Testosterone in women → only transdermal, only postmenopausal HSDD, only after failure of other options; physiologic premenopausal range.

Pelvic floor PT is underutilized and is first-line for nearly every painful sexual disorder.

FSFI is the validated screening/tracking tool (19 items, 6 domains).

Vaginal pH >5 in postmenopausal woman = atrophy/GSM.

Persistent genital arousal disorder (PGAD) is distinct from HSDD — refer to specialist.

Energy-based vaginal devices are not recommended outside trials (FDA warning).

Hyperprolactinemia → low desire + galactorrhea + amenorrhea → check pituitary MRI.

Board Question Stem Patterns

Step 3 management: Pattern-recognize the dominant problem (desire/arousal/orgasm/pain), identify reversible contributors, choose the most specific first-line therapy — this algorithm answers the majority of FSD vignettes.

Stem 1 — SSRI-induced anorgasmia: 38-year-old woman 6 months into sertraline for MDD reports inability to orgasm and decreased libido; mood improved. Best next step? → Switch to bupropion or augment with bupropion (not add sildenafil first; not stop antidepressant).

Stem 2 — Postmenopausal dyspareunia: 62-year-old with vaginal dryness, dyspareunia, exam shows pale thin mucosa, pH 6. Best initial therapy? → Lubricants + vaginal moisturizers, then low-dose vaginal estrogen if inadequate.

Stem 3 — Provoked vestibulodynia: 28-year-old with entry dyspareunia × 1 year, exam normal except tenderness on Q-tip at 5 and 7 o'clock. Diagnosis and treatment? → Provoked vestibulodynia → topical lidocaine + pelvic floor PT.

Stem 4 — Vaginismus/GPPPD: Newly married 24-year-old, unable to consummate, exam reveals reflexive pelvic floor spasm with attempted insertion. Best initial management? → Pelvic floor PT + graded vaginal dilators + CBT.

Stem 5 — Premenopausal HSDD: 35-year-old, generalized acquired low desire, distressed, partner relationship intact, no medications, normal exam and labs. Pharmacotherapy option? → Flibanserin or bremelanotide after counseling.

Stem 6 — Lichen sclerosus: 55-year-old postmenopausal woman with vulvar itching, white atrophic plaques, dyspareunia. Diagnosis and management? → Biopsy to confirm, then topical clobetasol; annual surveillance.

Stem 7 — Breast cancer survivor: Tamoxifen/AI patient with severe GSM unresponsive to lubricants. Next step? → Discuss with oncology; consider vaginal DHEA, ospemifene, or low-dose vaginal estrogen.

Stem 8 — Postpartum FSD: 6-week visit, breastfeeding mother with dyspareunia, low desire. Best counseling? → Reassurance, lubricants, PPD screening, pelvic floor exercises; defer pharmacotherapy.

Stem 9 — Hyperprolactinemia: Low desire + galactorrhea + amenorrhea on no medications → Prolactin level, pituitary MRI.

Stem 10 — IPV disclosure: During FSD evaluation, patient discloses partner sexual coercion → Private safety assessment, resources, safety plan; not mandatory reporting in most states.

One-Line Recap

Female sexual dysfunction is a distress-defined, biopsychosocial diagnosis whose evaluation centers on identifying the dominant problem (desire, arousal, orgasm, or pain), reversing contributors (medications, hormones, mood, relationship, trauma), and matching first-line therapy — pelvic floor PT, vaginal estrogen/DHEA/ospemifene for GSM, flibanserin/bremelanotide for premenopausal HSDD, and sex therapy/CBT — before escalating to off-label or procedural options.

— GSM/dyspareunia → vaginal estrogen, DHEA, or ospemifene + lubricants

— Premenopausal HSDD → flibanserin or bremelanotide after non-pharmacologic measures

— GPPPD/vaginismus/vulvodynia → pelvic floor PT + dilators + topical lidocaine + CBT

— Orgasmic disorder → directed masturbation, vibrators, switch SSRI

Board pearl: When in doubt on a Step 3 FSD vignette, the safest answer combines screening for reversible contributors (medication review, PHQ-9, TSH, prolactin), pelvic floor PT referral when pain is present, and shared decision-making before any FDA-approved or off-label pharmacotherapy — this triad reflects guideline-concordant, exam-favored ambulatory practice.

Distress is the diagnostic gatekeeper — without it, there is no disorder.

Reversible causes first: SSRIs (switch to bupropion), hypothyroidism, hyperprolactinemia, GSM, depression, relationship stress, IPV — address before adding new drugs.

Match therapy to subtype:

Multidisciplinary care wins: primary care quarterbacks, with parallel referrals to pelvic floor PT, sex therapy/CBT, and gynecology — and integration of mental health, oncology, or endocrinology as indicated.